source
- FDA approves Mimrylo, first hepcidin-mimicking drug for polycythemia veraThe U.S. Food and Drug Administration announced approval of Mimrylo (rusfertide) for adult patients with polycythemia vera, a rare blood disorder that causes excess red blood cells. The drug mimic…
- AstraZeneca’s ATTR-CM Silencer Trial Fails to Show Benefit Over Existing Stabilizer TherapyAstraZeneca announced that its Phase 3 trial of a silencer drug for transthyretin amyloid cardiomyopathy (ATTR-CM) did not meet its primary endpoints. The study showed no additional clinical benefi…